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Cryptococcosis has evolved into a major invasive fungal disease over the last century. Its primary epi-
demiology has been focused on three major outbreaks of disease that reﬂects both changing environmen-
tal exposures and growth of host risk factors. The molecular understandings of yeast pathobiology have
been bolstered by identiﬁcation of the yeast’s dynamic genomic structures and functions. It is during
these new insights into epidemiology and pathobiology that we have also improved our diagnosis of this
infection with a new point-of-care, simple, cheap test which utilizes a lateral ﬂow assay for antigen
detection. With methods for effective identiﬁcation of Cryptococcus in the host, the principles for manage-
ment of this deadly infection include both use of old drugs and new insights into treatment strategies to
improve outcome. In this review there are a series of recent insights, opinions, and facts which attempt to
summarize our present knowledge base for this deadly fungal central nervous system infection with a
particular emphasis on its diagnosis and management.
 2014 The Authors. Published by Elsevier Inc. This is an open access article under theCCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
From its humble beginnings as a single case report in 1895 to its
worldwide explosion of disease with a million cases per year as the
HIV epidemic peaked (Park et al., 2009), Cryptococcus has achieved
a major place in clinical mycology as the ‘‘sugar-coated’’ (polysac-
charide capsule) yeast that can efﬁciently kill the susceptible host
with and without treatment. Furthermore, it represents a major
fungal model system for the study and development of principles
in fungal pathogenesis, diagnosis, and treatment. This yeast has a
mature molecular biology foundation with over 100 genetic loci
linked to its virulence composite and widespread genomic, tran-
scriptomic and proteomic studies available for study. Its diagnosis
is supported on several levels by routine culture techniques, a
well-described histopathology and the best validated serological
tests in all of medical mycology. Finally, its treatment principles
are supported by some of the most robust clinical studies in inva-
sive fungal diseases.2. The dynamic yeast
Cryptococcosis is caused primarily by two fungal species,
Cryptococcus neoformans and Cryptococcus gattii, and these specieshave been further sub-divided into several genotypes (VNI, VII,
VNB, VNIV, and VGI-IV) and only in rare circumstances are other
cryptococcal species found to cause human disease. The taxonomy
and population genetics of these two species continue to be evalu-
ated and with the widespread and effective use of Multiple Locus
Sequence Typing (MLST) analysis and whole genome sequencing,
understanding strain heritage has become even more precise. Of
the human pathogenic fungi, the two Cryptococcus species repre-
sent one of the most robust MLST fungal databases and with whole
genome sequencing platforms, detailed analyses of strains will
greatly expand soon. Recent genomic studies have begun to
emphasize a very important principle: the cryptococcal genomes
display impressive plasticity and capacity for microevolution.
These changes in the cryptococcal genome structure can occur
with strain passage in vitro or be frequently observed in the stress
environment of the human subarachnoid space (Hu et al., 2011;
Janbon et al., 2014). Furthermore, it has been observed that even
within clinical strains isolated from infected patients that there
are genomic differences noted and certain speciﬁc genotypes have
been associated with a poor clinical prognosis (Wiesner et al.,
2012). These observations challenge medical mycologists to char-
acterize the precise whole genetic virulence composite of these
strains beyond their obvious genetic controls of the classical viru-
lence phenotypes such as capsule and melanin production, high
temperature growth, and phospholipase/urease activity.
The virulence composite of this encapsulated yeast is clearly
multigenetic, changing, and complex. First, it has been shown that
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in the human subarachnoid space, functionally react both similarly
and differently with respect to their regulation of stress responses
and transporter genes in order to survive in this harsh host envi-
ronment (Chen et al., 2014). Second, the dynamic mechanism of
heteroresistance to ﬂuconazole in Cryptococcus spp. that has been
elegantly described (Sionov et al., 2010) has now importantly been
shown to be relevant in vivo (Sionov et al., 2013). For instance, drug
resistance can result from stress-induced chromosomal plasticity
and aneuploidy formation involving gene duplications of the tar-
get(s) or azole efﬂux pumps. Therefore, under in vivo stress there
is resistance to high concentrations of ﬂuconazole through gene
duplications for the ergosterol targets or efﬂux pumps. This drug
resistant phenotypic observation likely occurs in patients with a
high burden of yeasts in cerebrospinal ﬂuid (CSF) during the fungi-
static effects of ﬂuconazole treatment. However, when the yeast is
isolated from the host and grown in vitro under fully nutritious
conditions, this aneuploidy is resolved and the yeast is now again
phenotypically susceptible to the azole. This disconnect between
in vitro antifungal susceptibility testing for Cryptococcus may be
fundamentally confusing to the clinician simply due to the genetics
and pathobiology of the yeast. It potentially adds to the uncer-
tainty of precise ‘‘clinical in vitro break-points’’ for azoles in cryp-
tococcosis management. Third, even the simple but dynamic
human biological ﬂuid, CSF, represents a dynamic challenge to this
yeast which must meet this harsh environment with a series of
genetic controls for adaptation (Lee et al., 2012). Fourth, it is also
important to emphasize that in many respects the general pheno-
typic and genetic responses are used similarly by both C. neofor-
mans and C. gattii strains. However, there are some differences
between these species, reﬂecting their approximately 40 million
year genetic separation and thus pathophysiology will not be
exactly the same (Ngamskulrungroj et al., 2009, 2012).
Although we are beginning to understand the population genet-
ics of this clinically important group of basidiomycetes and have
been able to identify genetic variations which will be helpful for
epidemiological purposes and even possibly detect differences in
relapse vs persistent cryptococcal strains (Van Wyk et al., 2014),
does the clinician yet beneﬁt from this genetic scrutiny and is this
information ready for the clinical microbiology laboratory? The
answer at this stage is probably ‘‘no’’. At present, there is a simple
biochemical difference to distinguish C. neoformans and C. gattii
with the use of a canavanine–bromothymol–glycine (CBG) agar
plate assay that allows separation of the two species by the color
of colonies. The species can also be distinguished by an array of
sequencing techniques and even MALDI-TOF can rapidly separate
species (Posteraro et al., 2012). While these techniques can sepa-
rate species and genotypes, the ability for the clinician to use this
information does not necessarily translate into differences in treat-
ment for C. neoformans vs C. gattii or speciﬁc genotypes. There have
been clinical comparative analyses between the two species (Smith
et al., 2014) but it remains difﬁcult to determine whether differ-
ences in therapeutic outcome are due to species variations as
opposed to the impact of underlying host immunity.3. Epidemiology: The three-part outbreak of cryptococcosis
The understanding of the epidemiology of this disease has been
helpful to put the diagnostic strategies in perspective. The appear-
ance of cryptococcosis continues to evolve around the world. It had
been estimated that there were greater than 600,000 deaths from
cryptococcosis at the peak of the HIV pandemic (Park et al.,
2009), but this ﬁgure has now been reduced by the impact of effec-
tive antiretroviral therapies reaching many locations in the world.
Although antiretroviral therapies have not ended the substantialworldwide impact of cryptococcosis in AIDS patients, they have
made an impact on its appearance. The second recent clinical cryp-
tococcal outbreak has occurred over the last two decades with C.
gattii infections identiﬁed in Vancouver, British Columbia and the
Northwest USA. The origins of this outbreak have been and con-
tinue to be extensively pursued to understand the reason(s) for
the appearance of these hypervirulent cryptococcal strains
(Billmyre et al., 2014; Engelthaler et al., 2014; Hagen et al.,
2013). At least one hypothesis is that climatic changes allowed
these cryptococcal strains to compete in the environmental micro-
biome and with increased exposure infect susceptible hosts.
Clinicians need to be aware of this new geographical range of C.
gattii in their immunocompetent and immunocompromised popu-
lations. There may presently be a reduced number of cases in this
particular epidemic in the Paciﬁc Northwest but the range of C. gat-
tii strains appears to be expanding and cases are now being identi-
ﬁed in Europe and the eastern USA (Harris et al., 2013).
The other ongoing outbreak of cryptococcosis started in the 196
0’s–1970’s as clinicians developedmedical programs in organ trans-
plantation and aggressive treatments of cancers and connective tis-
sue diseases (Pyrgos et al., 2013). With an immunosuppressive
armentarium of therapeutics, there has been a steady stream of
cryptococcosis cases and with the use of new immunosuppressive
biological agents such as anti-TNF and anti-CD54 monoclonal anti-
bodies, the clinician must constantly be aware of cryptococcosis in
their differential diagnosis, particularly in high endemic areas and
with identiﬁed risk factors. For instance, cryptococcosis is wide-
spread in the world but certain areas such as sub-Saharan Africa
and the southeastern USA appear to have particularly high (ende-
mic) infection rates. In fact, patients who do not have an underlying
HIV infection or are not transplant recipients are remarkably now
the highest risk group for mortality in resource-available countries
(Bratton et al., 2013). This group, in which mortality can reach
>30% in these developed countries, tends tohave adelayeddiagnosis
compared to the HIV and transplant groups and this ﬁnding empha-
sizes that a critical factor in improving outcome is earlier diagnosis
of thedisease. It is also important to note that this is a heterogeneous
groupwithmany underlying diseases that inﬂuence outcome; how-
ever, there is a subgroup of cases that has no apparent underlying
disease yet develops disseminated cryptococcosis. This subgroup
generally has a better prognosis for positive outcome and although
individuals probablyhaveanaltered immunesystem, it is not as sev-
ere as many other patient groups with cryptococcosis. Recently,
some of these apparently normal hosts with disseminated crypto-
coccosis were found to possess an immunological perturbation by
producing abundant anti-GM-CSF antibodies (Rosen et al., 2013;
Saijo et al., 2014). Furthermore, studies are beginning to identify
human genetic variants in immune genes linked to susceptibility
for cryptococcosis (Rohatgi et al., 2013). Therefore, risk factors for
cryptococcosis aremany and can be complex.We can identify some
factors clinically but others are buried in our genomes. Thus, the
clinician must consider this invasive fungal infection in a variety
of circumstances and institute the excellent diagnostic strategies
that have been developed.4. Diagnosis: The maturation of identiﬁcation
The diagnosis of cryptococcosis, after 100 years of experience, is
relatively facile with multiple methods and improved diagnostic
strategies. The techniques include direct examination of the fungus
inbodyﬂuidswith India ink examination, histopathology of infected
tissue with speciﬁc stains to identify capsule (mucicarmine and
alcian blue) or presence of melanin (Fontana-Masson), serology
from body ﬂuids and culture of ﬂuids and/or tissues. Despite these
multiple strategies tomake the diagnosis, the clinician, without risk
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ease, can fail to make an early diagnosis of disseminated cryptococ-
cosis that might be critical to outcome. For example, it has been
shown that from the beginning time of symptoms both
HIV-infected and transplant patients are diagnosed with cryptococ-
cal meningitis within 2–3 weeks. On the other hand, those without
these risk factors may take twice as long to make the diagnosis
and patient outcome with treatment is worse (Bratton et al.,
2012). Therefore, despite our diagnostic tools, the critical factor for
best outcome will be the clinician’s risk assessment and considera-
tion of cryptococcal meningitis in the diagnosis during early symp-
toms to then apply these diagnostic strategies.
The diagnostic methods such as histopathology and cultures are
well-described in a series of reviews and books (Heitman et al.,
2011; Perfect, 2013). The diagnostic area with the most recent evo-
lution has been the serological diagnosis of cryptococcosis. The
diagnostic use for detection of cryptococcal capsular polysaccha-
ride in serum and cerebrospinal ﬂuid by Latex Agglutination or
ELISA has been available for over 35 years and this testing system
has an overall sensitivity and speciﬁcity of 93–100% and 93–98%,
respectively. The false positive rate is less than 1% and generally
is explained by technical issues or other infections (including a
cross reaction with antigens from Trichosporon species). These tests
can occasionally yield a false negative output in early infections,
but more commonly can be positive before the detection of viable
cryptococcal colonies obtained through cultures.
A lateral ﬂow assay (LFA) was recently introduced into the diag-
nostic repertoire for cryptococcosis (Hansen et al., 2013;
Rugemalila et al., 2013). The semi-quantitative LFA offers many
advantages including rapid turnaround time, minimal require-
ments for a specialized laboratory with potential use at ‘‘point of
care’’ and low costs. The LFA has been compared to Latex
Agglutination, ELISA and cultures with excellent concordance. It
works well in resource-limited settings and can even pick up some
C. gattii infections not detected by the other serological tests. This
LFA is now being instituted in clinical practice and studies have
begun as a ‘‘point-of-care’’ testing for pre-emptive administration
of antifungals in resource-limited settings with a high incidence
of HIV and cryptococcal diseases. The present hypothesis is that
persons with HIV infection and isolated cryptococcal polysaccha-
ride antigenemia beneﬁt from early antifungal therapy to prevent
or delay the development of disseminated disease, notably menin-
gitis. For example, prevalence of asymptomatic cryptococcal anti-
genemia in patients with CD4 cell counts <100/lL ranges from
2% to 21% in certain geographical locations (Meya et al., 2010).
With an accurate ‘‘point of care’’ test, strategies of diagnostic inter-
vention and pre-emptive therapy are being implemented and
tested in Uganda, Rwanda, Mozambique and South Africa. Even
in the USA, a recent Centers for Disease Control study found a 3%
prevalence in almost 2000 blood samples from HIV-infected
patients taken between 1986 and 2012, a ﬁgure that is above the
cost-effectiveness threshold for the introduction of a
‘‘screen-and-treat’’ program to effectively manage cryptococcosis
during HIV infection (McKenney et al., 2014; Meya et al., 2010).
With an accurate ‘‘point-of-care’’ test, these early, precise strate-
gies of diagnostic intervention and pre-emptive therapy should
be considered, implemented and/or tested.
Polysaccharide antigen testing has two other important princi-
ples. First, a baseline high titer of polysaccharide antigen in serum
or CSF carries prognostic signiﬁcance, in that a high titer (>1:1024)
is associated with a large burden of yeasts and a high viable quan-
titative yeast count in CSF is a predictor of death during systemic
antifungal therapy (Jarvis et al., 2014). Second, the elimination
kinetics of polysaccharide in the host are not precise and it is
important to recognize that the use of changing polysaccharide
antigen titers to make therapeutic decisions should be done withcaution and in relationship to other clinical factors. Another test
in cryptococcal meningitis is the viable quantitative CSF yeast
count, that may allow both appreciation of fungal burden and even
be used for therapeutic monitoring by measurement of the early
fungicidal activity (EFA) with serial quantitative CSF yeast mea-
surements during antifungal treatment (Day et al., 2013). This test
has been used as an effective research tool but has not yet been
integrated into routine clinical practice. As we consider more use-
ful and precise follow-up lumbar punctures, this measurement
could be insightful for management. Furthermore, the ongoing
evaluation of EFA as a potential surrogate marker in cryptococcal
meningitis is important if it is to be used in the process of regula-
tory approval of novel anti-cryptococcal agents.5. The evolution of therapeutic strategies
The antifungal arsenal for treatment against cryptococcosis cur-
rently is largely limited to three old and off-patent drugs, used sin-
gly or in combination: amphotericin B (and its liposomal
derivatives), 5-ﬂuorocytosine (5FC) and ﬂuconazole. For cryptococ-
cal meningitis, treatment is split into three phases: an initial
2-week induction therapy with a fungicidal amphotericin
B-based regimen, followed by 8-week consolidation therapy and
subsequently maintenance therapy with ﬂuconazole, continued
for 6–12 months and/or until restoration of host immunity
(Perfect et al., 2010).
The evidence base for therapy of cryptococcal meningitis, both
in the pre- and post-HIV era, is some of the best in all of medical
mycology. Numerous trials using mycological endpoints, including
time to and rate of CSF sterilization (EFA), demonstrated the supe-
rior efﬁcacy of the combination of amphotericin B deoxycholate
and 5FC (Bennett et al., 1979; Brouwer et al., 2004; Day et al.,
2013; Larsen et al., 1990; van der Horst et al., 1997). The place of
this combination as the ‘‘gold standard’’ treatment for cryptococcal
meningitis is in both the Infectious Disease Society of America and
World Health Organization (WHO) Treatment Guidelines and was
recently re-afﬁrmed by a large clinical trial in Vietnam (n = 299),
showing both a more rapid fungicidal response and a concomitant
signiﬁcant survival advantage for this combination compared to
amphotericin B alone (Day et al., 2013).
Despite consistent treatment guideline recommendations from
several sources, worldwide access to the antifungal drugs remains
woefully inadequate. For example, the main stay fungicidal drug,
amphotericin B deoxycholate, use is hampered by cost, inadequate
supply chains and difﬁculties with monitoring and managing its
life-threatening adverse events of nephrotoxicity and anaemia
(Loyse et al., 2013). Pre-emptive hydration and electrolyte replace-
ment can mitigate some of these side effects and are now recom-
mended by the WHO (Anonymous, 2011). Furthermore, shorter
courses of 5–7 days of amphotericin B deoxycholate offer a com-
promise, with animal model and human data demonstrating simi-
lar rates of fungal clearance from the central nervous system in the
second week following treatment that is compatible with the
drug’s long half-life (Jackson et al., 2012; Livermore et al., 2013;
Muzoora et al., 2012). The much costlier liposomal amphotericin
B preparations have similar efﬁcacy with fewer toxicities (Hamill
et al., 2010) and are widely used in resource-rich settings, particu-
larly for non-HIV patients who are frequently on concomitant
nephrotoxic agents and in many clinical situations, such as trans-
plant recipients, these formulations are used as primary therapy.
Even in resource-limited areas, a trial exploring the EFA of one to
three intermittent high doses (5–10 mg/kg/d) of AmBisome
(Gilead Sciences Inc.) is commencing to optimize its safety and
long half-life activity in resource-poor settings (AmBition-CM,
www.controlled-trials.com/ISRCTN10248064).
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adherence to four times daily dosing and bone marrow toxicity.
5FC has just two manufacturers and is not registered in any
African country (Loyse et al., 2013). Advocacy efforts are underway
to promote generic manufacture of 5FC and encourage the devel-
opment of a slow release formulation. Fluconazole, used in the
consolidation and maintenance phases of treatment as well as in
pre-emptive treatment of antigenemic patients as part of
pre-ART screening programs, remains widely available via Pﬁzer’s
Diﬂucan donation program as well as through cheap generics
(Loyse et al., 2013). Used for induction therapy, it is fungistatic at
the historically-used doses of 400 mg/d (Bicanic et al., 2007).
Higher dosing at 800–1200 mg/d (Longley et al., 2008;
Mayanja-Kizza et al., 1998), in particular when combined with
5FC (Nussbaum et al., 2010), have improved mycological efﬁcacy
and hold promise as an all-oral induction treatment regimen for
settings where intravenous amphotericin B simply cannot safely
be given. An ongoing ACTG trial of ﬂuconazole is assessing
10-week CSF culture conversion, survival and safety of even higher
ﬂuconazole doses of up to 2 g/d [clinicaltrials.gov/
show/NCT00885703]. A large multi-site African randomized trial
(ACTA, www.controlled-trials.com/ISRCTN45035509) is comparing
ﬂuconazole at 1200 mg/d plus 5FC to one or 2-week amphotericin-
based induction regimens.
Even with access to amphotericin B based treatment and
antiretroviral therapy (ART), early (3-month) mortality outside of
clinical trial settings remains high at 35–40% in both some
resource-rich and resource-poor settings (Brizendine et al., 2013;
Lightowler et al., 2010; Siddiqi et al., 2014). In resource-rich settings,
non-HIV, non-transplant patients tend to fare worse, partly because
of delayed diagnosis due to lack of clinical suspicion and heteroge-
neous underlying diseases (Bratton et al., 2013). In HIV-infected
patients in resource-poor settings, late presentation is common
due to lack of access to diagnostic facilities, which the
‘‘point-of-care test’’ LFA, that also detects cryptococcal antigen in
urine, attempts to address. Altered mental status (Glasgow Coma
Scale (GCS) < 15 and/or seizures and abnormal behavior) is themost
signiﬁcant predictor of early death (Jarvis et al., 2014) yet its patho-
physiology remains poorly understood; we do not even understand
whether this is driven by either fungal or host factors.
Raised intracranial pressure is an extremely common complica-
tion of cryptococcal meningitis and is associated with sometimes
profound and irreversible visual and hearing loss (Graybill et al.,
2000). Whilst host factors may play a role, there is evidence for
pathophysiology due to fungal factors, with a combination of a
high fungal burden and infection with highly encapsulated strains
obstructing CSF outﬂow and causing a communicating hydro-
cephalus (Bicanic et al., 2009; Robertson et al., 2014). Raised
intracranial pressure will resolve with time, so to avert irreversible
morbidity, management is by frequent, sometimes daily, large vol-
ume (up to 30–40 ml) therapeutic CSF taps or temporary diversion
using lumbar or ventricular drains (Perfect et al., 2010).
Performance of these interventions is frequently suboptimal in
all settings due to doctors’ lack of knowledge, motivation and
equipment (disposable manometers) and patients’ fear of lumbar
punctures, particularly prevalent in some African countries, but
attention to serial lumbar punctures generally has a positive
impact on outcome (Rolfes et al., 2014).
The clinical management of disseminated cryptococcosis must
critically take into account the infected host’s immune status.
Although the disease affects mainly the immunosuppressed host
either in HIV-infected or non-HIV-infected (largely iatrogenic
immunosuppression for organ transplant or chronic inﬂammatory
conditions) patients, it can also occur in the immunocompetent
host, particularly in China and Australia (Chen et al., 2013; Zhu
et al., 2010). As a general rule, the ART-naïve HIV patient has a highfungal burden with a paucity of inﬂammation, whilst non-HIV
patients and HIV patients presenting post-ART have lower fungal
burdens with more CSF inﬂammation (Bicanic et al., 2007;
Bratton et al., 2013). Immunopathology can also vary over time
within the same host following restoration of immune function.
Corticosteroids that represent a major risk factor for disseminated
cryptococcosis can also be needed to control excess inﬂammation
in the treatment of immunocompetent patients with C. gattii infec-
tion (Seaton et al., 1997) and for immune reconstitution inﬂamma-
tory syndrome (IRIS) in HIV and other conditions such as
transplant recipients. A large trial is currently addressing the
impact of adjunctive dexamethasone on 10-week survival in
ART-naïve and ART-experienced HIV-infected patients presenting
with cryptococcal meningitis (CRYPTODEX, www.controlled-tri-
als.com/ISRCTN59144167).
However, in immunocompromised hosts, augmentation and
restoration of host immunity through reversal of immunosuppres-
sion or ART in HIV-infected hosts is necessary to clear infection.
Interferon gamma is a key pro-inﬂammatory cytokine (Jarvis
et al., 2013) whose levels correlate with rate of fungal clearance
and are of prognostic signiﬁcance (Jarvis et al., 2014; Siddiqui
et al., 2005). Augmentation of the poor pro-inﬂammatory
responses characteristic of patients with advanced HIV using
interferon-gamma as adjunctive therapy has led to improved fun-
gal clearance (Jarvis et al., 2012), but this recombinant cytokine
still primarily is used in the clinics as adjunctive therapy in those
who microbiologically fail antifungal therapy.
In HIV patients in whom cryptococcal meningitis usually pre-
sents at CD4 counts below 100 cells/lL, ART should be commenced
following the completion of the antifungal induction treatment, ide-
ally once CSF is sterile. Competing risks must be balanced: starting
ART too early runs the risk of paradoxical IRIS in response to residual
fungus and its polysaccharide antigen; starting too late risk patients’
death from other incident opportunistic infections or disease com-
plications. IRIS is characterized by rapid but dysregulated
pathogen-speciﬁc immune restoration, and can occur in both the
HIV and non-HIV-infected host, in response to lowering of doses of
immunosuppression (Gupta and Singh, 2011). There are no random-
ized trial data to inform our management of IRIS: a combination of
ART continuation, management of raised intracranial pressure and
a short course of tapering doses of steroids for those with persistent
symptoms is recommended (Perfect et al., 2010).
Cryptococcal IRIS in the conﬁned space of the central nervous
system can be particularly detrimental, occurring in up to
13–30% of HIV-infected patients in published series, usually in
the early months on ART (Longley et al., 2013). The recently
published COAT trial (n = 177) randomized patients to early
(1–2 weeks, median 9 days from start of cryptococcal meningitis
induction treatment) vs delayed start of ART (5 weeks) (Boulware
et al., 2014). There was excess mortality in the early group and
thus the trial was stopped early. Although there were no signiﬁcant
differences in IRIS incidence, the difference in mortality appeared
to be driven by patients with a lack of CSF inﬂammation
(WBC < 5/lL) at randomization, who died soon after starting ART,
with the excess of deaths judged to be due to cryptococcal menin-
gitis. The ﬁndings of this trial suggest starting ART between 1 and
2 weeks of induction therapy is too early, but does not inform us
about starting ART at later time points between 2 and 5 weeks.
Given that high fungal burden and a poor CSF pro-inﬂammatory
response (together with high chemokine levels) pre-ART have both
been shown to be risk factors for IRIS (Boulware et al., 2010; Jarvis
et al., 2014), a practical point may to use a combination of CSF
quantitative cryptococcal cultures and CSF white cell counts at
the end of week 2 to determine those patients (sterile CSF with evi-
dence of CSF inﬂammation) in whom it may be safe to start ART at
3–4 weeks, but this strategy has not been tested.
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previously subclinical infection presenting with cryptococcal
meningitis in the ﬁrst months following start of ART. In African
cohorts, 20–30% of new cryptococcal meningitis cases now present
in ART-experienced patients. These patients may now be identiﬁed
and cases prevented with pre-ART screening and treatment of
asymptomatic cryptococcal antigenemia with high dose ﬂucona-
zole (Jarvis et al., 2012). Symptoms as well as the titer of antigen-
emia may again have prognostic implications and indicate which
patients might need referral for a lumbar puncture to rule out
meningitis (Jarvis et al., 2009).
In sum, cryptococcosis is in a state of evolution, from the organ-
ism, to the host, to the guidelines for diagnosis and treatment. We
know a lot but still not enough! The sugar-coated yeast still sickens
and we need to manage it better.References
Anonymous, 2011. Rapid Advice. Diagnosis, Prevention and Management of
Cryptococcal Disease in HIV-infected Adults, Adolescents and Children. WHO
Press, Geneva, Switzerland.
Bennett, J.E., Dismukes, W.E., Duma, R.J., et al., 1979. A comparison of amphotericin
B alone and combined with ﬂucytosine in the treatment of cryptococcal
meningitis. N. Engl. J. Med. 301, 123–131.
Bicanic, T., Meintjes, G., Wood, R., Hayes, M., Rebe, K., Bekker, L.G., Harrison, T., 2007.
Fungal burden, early fungicidal activity, and outcome in cryptococcal
meningitis in antiretroviral-naive or antiretroviral-experienced patients
treated with amphotericin B or ﬂuconazole. Clin. Infect. Dis. 45, 76–80.
Bicanic, T., Brouwer, A.E., Meintjes, G., Rebe, K., Limmathrotsakul, D., Chierakul, W.,
Teparrukkul, P., Loyse, A., 2009. Relationship of cerebrospinal ﬂuid pressure,
fungal burden and outcome in patients with cryptococcal meningitis
undergoing serial lumbar punctures. AIDS 23, 701–706.
Billmyre, R.B., Croll, D., Li, W., Mieczkowski, P., Carter, D.A., Cuomo, C.A., Kronstad,
J.W., Heitman, J., 2014. Highly recombinant VGII Cryptococcus gattii population
develops clonal outbreak clusters through both sexual macroevolution and
asexual microevolution. mBio 5, e01494.
Boulware, D.R., Bonham, S.C., Meya, D.B., Wiesner, D.L., Park, G.S., Kambugu, A.,
Janoff, E.N., Bohjanen, P.R., 2010. Paucity of initial cerebrospinal ﬂuid
inﬂammation in cryptococcal meningitis is associated with subsequent
immune reconstitution inﬂammatory syndrome. J. Infect. Dis. 202, 962–970.
Boulware, D.R., Meya, D.B., Muzoora, C., Rolfes, M.A., Huppler Hullsiek, K., Musubire,
A., Taseera, K., Nabeta, H.W., Schutz, C., Williams, D.A., Rajasingham, R., Rhein, J.,
Thienemann, F., Lo, M.W., Nielsen, K., Bergemann, T.L., Kambugu, A., Manabe,
Y.C., Janoff, E.N., Bohjanen, P.R., Meintjes, G., Team, C.T., 2014. Timing of
antiretroviral therapy after diagnosis of cryptococcal meningitis. N. Engl. J. Med.
370, 2487–2498.
Bratton, E.W., El Husseini, N., Chastain, C.A., Lee, M.S., Poole, C., Sturmer, T., Juliano,
J.J., Weber, D.J., Perfect, J.R., 2012. Comparison and temporal trends of three
groups with cryptococcosis: HIV-infected, solid organ transplant, and HIV-
negative/non-transplant. PLoS One 7, e43582.
Bratton, E.W., El Husseini, N., Chastain, C.A., Lee, M.S., Poole, C., Stürmer, T., Weber,
D.J., Juliano, J.J., Perfect, J.R., 2013. Approaches to antifungal therapies and their
effectiveness among patients with cryptococcosis. Antimicrob. Agents
Chemother. 57, 2485–2495.
Brizendine, K.D., Baddley, J.W., Pappas, P.G., 2013. Predictors of mortality and
differences in clinical features among patients with cryptococcosis according to
immune status. PLoS One 8, e60431.
Brouwer, A.E., Rajanuwong, A., Chierakul, W., Grifﬁn, G.E., Larsen, R.A., White, N.J.,
Harrison, T.S., 2004. Combination antifungal therapies for HIV-associated
cryptococcal meningitis: feasibility and power of quantitative CSF cultures to
determine fungicidal activity. Lancet 363, 1764–1767.
Chen, S.C., Korman, T.M., Slavin, M.A., Marriott, D., Byth, K., Bak, N., Currie, B.J.,
Hajkowicz, K., Heath, C.H., Kidd, S., McBride, W.J., Meyer, W., Murray, R.,
Playford, E.G., Sorrell, T.C., Australia, New Zealand Mycoses Interest Group
Cryptococcus, 2013. Antifungal therapy and management of complications of
cryptococcosis due to Cryptococcus gattii. Clin. Infect. Dis. 57, 543–551.
Chen, Y., Toffaletti, D.L., Tenor, J.L., Litvintseva, A.P., Fang, C., Mitchell, T.G.,
McDonald, T.R., Nielsen, K., Boulware, D.R., Bicanic, T., Perfect, J.R., 2014. The
Cryptococcus neoformans transcriptome at the site of human meningitis. mBio 5,
e01087-13.
Day, J.N., Chau, T.T., Wolbers, M., 2013. Combination antifungal therapy for
cryptococcal meningitis. N. Engl. J. Med. 368, 1291–1302.
Engelthaler, D.M., Hicks, N.D., Gillece, J.D., Roe, C.C., Schupp, J.M., Driebe, E.M.,
Gilgado, F., Carriconde, F., Trilles, L., Firacative, C., Ngamskulrungroj, P.,
Castañeda, E., dos Santos Lazera, M., Melhem, M.S.C., Pérez-Bercoff, Å.,
Huttley, G., Sorrell, T.C., Voelz, K., May, R.C., Fisher, M.C., Thompson 3rd, G.R.,
Lockhart, S.R., Keim, P., Meyer, W., 2014. Cryptococcus gattii in North American
Paciﬁc Northwest: whole-population genome analysis provides insights into
species evolution and dispersal. mBio 5, e01464.Graybill, J.R., Sobel, J., Saag, M., van der Horst, C., Powderly, W., Cloud, G., Riser, L.,
Hamil, R.J., Dismukes, W., 2000. Diagnosis and management of increased
intracranial pressure in patients with AIDS and cryptococcal meningitis. Clin.
Infect. Dis. 30, 47–54.
Gupta, A.O., Singh, N., 2011. Immune reconstitution syndrome and fungal
infections. Curr. Opin. Infect. Dis. 24, 527–533.
Hagen, F., Ceresini, P.C., Polacheck, I., Ma, H., van Nieuwerburgh, F., Gabaldón, T.,
Kagan, S., Pursall, E.R., Hoogveld, H.L., van Iersel, L.J.J., Klau, G.W., Kelk, S.M.,
Stougie, L., Bartlett, K.H., Voelz, K., Pryszcz, L.P., Castañeda, E., Lazera, M., Meyer,
W., Deforce, D., Meis, J.F., May, R.C., Klaassen, C.H.W., Boekhout, T., 2013.
Ancient dispersal of the human fungal pathogen Cryptococcus gattii from the
Amazon rainforest. PLoS One 8, e71148.
Hamill, R.J., Sobel, J.D., El-Sadr, W., Johnson, P.C., Graybill, J.R., Javaly, K., Barker, D.E.,
2010. Comparison of 2 doses of liposomal amphotericin B and conventional
amphotericin B deoxycholate for treatment of AIDS-associated acute
cryptococcal meningitis: a randomized, double-blind clinical trial of efﬁcacy
and safety. Clin. Infect. Dis. 51, 225–232.
Hansen, J., Slechta, E.S., Gates-Hollingsworth, M.A., Neary, B., Barker, A.P., Bauman,
S., Kozel, T.R., Hanson, K.E., 2013. Large-scale evaluation of the immuno-
mycologics lateral ﬂow and enzyme-linked immunoassays for detection of
cryptococcal antigen in serum and cerebrospinal ﬂuid. Clin. Vaccine Immunol.
20, 52–55.
Harris, J.R., Lockhart, S.R., Sondermeyer, G., Vugia, D.J., Crist, M.B., D’Angelo, M.T.,
Sellers, B., Franco-Paredes, C., Makvandi, M., Smelser, C., Greene, J., Stanek, D.,
Signs, K., Nett, R.J., Chiller, T., Park, B.J., 2013. Cryptococcus gattii infections in
multiple states outside the US Paciﬁc Northwest. Emerg. Infect. Dis. 19, 1620–
1626.
Heitman, J., Kozel, T.R., Kwon-Chung, K.J., Perfect, J.R., Casadevall, A., 2011.
Cryptococcus: From Human Pathogen to Model Yeast. ASM Press, Washington,
DC, USA.
Hu, G., Wang, J., Choi, J., Jung, W.H., Liu, I., Litvintseva, A.P., Bicanic, T., Aurora, R.,
Mitchell, T.G., Perfect, J.R., Kronstad, J.W., 2011. Variation in chromosome copy
number inﬂuences the virulence of Cryptococcus neoformans and occurs in
isolates from AIDS patients. BMC Genom. 12, 526.
Jackson, A.T., Nussbaum, J.C., Phulusa, J., Namarika, D., Chikasema, M., Kanyemba, C.,
Jarvis, J.N., Jaffar, S., Hosseinipour, M.C., van der Horst, C., Harrison, T.S., 2012. A
phase II randomized controlled trial adding oral ﬂucytosine to high-dose
ﬂuconazole, with short-course amphotericin B, for cryptococcal meningitis.
AIDS 26, 1363–1370.
Janbon, G., Ormerod, K.L., Paulet, D., Byrnes 3rd, E.J., Yadav, V., Chatterjee, G.,
Mullapudi, N., Hon, C.-C., Billmyre, R.B., Brunel, F., Bahn, Y.-S., Chen, W., Chen, Y.,
Chow, E.W.L., Coppée, J.-Y., Floyd-Averette, A., Gaillardin, C., Gerik, K.J., Goldberg,
J., Gonzalez-Hilarion, S., Gujja, S., Hamlin, J.L., Hsueh, Y.-P., Ianiri, G., Jones, S.,
Kodira, C.D., Kozubowski, L., Lam, W., Marra, M., Mesner, L.D., Mieczkowski, P.A.,
Moyrand, F., Nielsen, K., Proux, C., Rossignol, T., Schein, J.E., Sun, S.,Wollschlaeger,
C., Wood, I.A., Zeng, Q., Neuvéglise, C., Newlon, C.S., Perfect, J.R., Lodge, J.K.,
Idnurm, A., Stajich, J.E., Kronstad, J.W., Sanyal, K., Heitman, J., Fraser, J.A., Cuomo,
C.A., Dietrich, F.S., 2014. Analysis of the genome and transcriptome of
Cryptococcus neoformans var. grubii reveals complex RNA expression and
microevolution leading to virulence attenuation. PLoS Genet. 10, e1004261.
Jarvis, J.N., Lawn, S.D., Vogt, M., Bangani, N., Wood, R., Harrison, T.S., 2009. Screening
for cryptococcal antigenemia in patients accessing an antiretroviral treatment
program in South Africa. Clin. Infect. Dis. 48, 856–862.
Jarvis, J.N., Meintjes, G., Rebe, K., Williams, G.N., Bicanic, T., Williams, A., Schutz, C.,
Bekker, L.G., Wood, R., Harrison, T.S., 2012. Adjunctive interferon-c
immunotherapy for the treatment of HIV-associated cryptococcal meningitis:
a randomized controlled trial. AIDS 26, 1105–1113.
Jarvis, J.N., Casazza, J.P., Stone, H.H., Meintjes, G., Lawn, S.D., Levitz, S.M., Harrison,
T.S., Koup, R.A., 2013. The phenotype of the Cryptococcus-speciﬁc CD4+ memory
T-cell response is associated with disease severity and outcome in HIV-
associated cryptococcal meningitis. J. Infect. Dis. 207, 1817–1828.
Jarvis, J.N., Bicanic, T., Loyse, A., Namarika, D., Jackson, A., Nussbaum, J.C., Longley,
N., Muzoora, C., Phulusa, J., Taseera, K., Kanyembe, C., Wilson, D., Hosseinipour,
M.C., Brouwer, A.E., Limmathurotsakul, D., White, N., van der Horst, C., Wood, R.,
Meintjes, G., Bradley, J., Jaffar, S., Harrison, T., 2014. Determinants of mortality
in a combined cohort of 501 patients with HIV-associated Cryptococcal
meningitis: implications for improving outcomes. Clin. Infect. Dis. 58, 736–745.
Larsen, R.A., Leal, M.A.E., Chan, L.S., 1990. Fluconazole compared with amphotericin
B plus ﬂucytosine for cryptococcal meningitis in AIDS. Ann. Intern. Med. 113,
183–187.
Lee, A., Toffaletti, D.L., Tenor, J., Soderblom, E.J., Thompson, J.W., Moseley, M.A.,
Price, M., Perfect, J.R., 2012. Survival defects of Cryptococcus neoformansmutants
exposed to human cerebrospinal ﬂuid result in attenuated virulence in an
experimental model of meningitis. Infect. Immun. 78, 4213–4225.
Lightowler, J.V., Cooke, G.S., Mutevedzi, P., Lessells, R.J., Newell, M.L., Dedicoat, M.,
2010. Treatment of cryptococcal meningitis in KwaZulu-Natal, South Africa.
PLoS One 5, e8630.
Livermore, J., Howard, S.J., Sharp, A.D., Goodwin, J., Gregson, L., Felton, T., Schwartz,
J.A., Walker, C., Moser, B., Muller, W., Harrison, T.S., Perfect, J.R., Hope, W.W.,
2013. Efﬁcacy of an abbreviated induction regimen of amphotericin B
deoxycholate for cryptococcal meningoencephalitis: 3 days of therapy is
equivalent to 14 days. mBio 5, e00725-13.
Longley, N., Muzoora, C., Taseera, K., Mwesigye, J., Rwebembera, J., Chakera, A., Wall,
E., Andia, I., Jaffar, S., Harrison, T.S., 2008. Dose–response effect of high-dose
ﬂuconazole for HIV-associated cryptococcal meningitis in southwestern
Uganda. Clin. Infect. Dis. 47, 1556–1561.
54 J.R. Perfect, T. Bicanic / Fungal Genetics and Biology 78 (2015) 49–54Longley, N., Harrison, T.S., Jarvis, J.N., 2013. Cryptococcal immune reconstitution
inﬂammatory syndrome. Curr. Opin. Infect. Dis. 26, 26–34.
Loyse, A., Thangaraj, H., Easterbrook, P., Ford, N., Roy, M., Chiller, T., Govender, N.,
Harrison, T.S., Bicanic, T., 2013. Cryptococcal meningitis: improving access to
essential antifungal medicines in resource-poor countries. Lancet Infect. Dis. 13,
629–637.
Mayanja-Kizza, H., Oishi, K., Mitarai, S., Yamashita, H., Nalongo, K., Watanabe, K.,
Izumi, T., Jungala, O., Augustine, K., Mugerwa, R., Nagatake, T., Matsumoto, K.,
1998. Combination therapy with ﬂuconazole and ﬂucytosine for cryptococcal
meningitis in Ugandan patients with AIDS. Clin. Infect. Dis. 26, 1362–1366.
McKenney, J., Smith, R.M., Chiller, T.M., Detels, R., French, A., Margolick, J., Klausner,
J.D., 2014. Prevalence and correlates of cryptococcal antigen positivity among
AIDS patients – United States, 1986–2012.Morb. Mortal.Wkly Rep. 63, 585–587.
Meya, D.B., Manabe, Y.C., Castelnuovo, B., Cook, B.A., Elbireer, A.M., Kambugu, A.,
Kamya, M.R., Bohjanen, P.R., Boulware, D.R., 2010. Cost-effectiveness of serum
cryptococcal antigen screening to prevent deaths among HIV-infected persons
with a CD4+ cell count 6100 cells/lL who start HIV therapy in resource-limited
settings. Clin. Infect. Dis. 51, 448–455.
Muzoora, C.K., Kabanda, T., Ortu, G., Ssentamu, J., Hearn, P., Mwesigye, J., Longley, N.,
Jarvis, J.N., Jaffar, S., Harrison, T.S., 2012. Short course amphotericin B with high
dose ﬂuconazole for HIV-associated cryptococcal meningitis. J. Infect. 64, 76–81.
Ngamskulrungroj, P., Himmelreich, U., Breger, J.A., Wilson, C., Chayakulkeeree, M.,
Krockenberger, M.B., Malik, R., Daniel, H.M., Toffaletti, D., Djordjevic, J.T.,
Mylonakis, E., Meyer, W., Perfect, J.R., 2009. The trehalose synthesis pathway is
an integral part of the virulence composite for Cryptococcus gattii. Infect.
Immun. 77, 4584–4596.
Ngamskulrungroj, P., Chang, Y., Sionov, E., Kwon-Chung, K.J., 2012. The primary
target organ of Cryptococcus gattii is different from that of Cryptococcus
neoformans in a murine model. mBio 3, e00103-12.
Nussbaum, J.C., Jackson, A., Namarika, D., Phulusa, J., Kenala, J., Kanyemba, C., Jarvis,
J.N., Jaffar, S., Hostetler, J., Hosseinipour, M.C., Kamwendo, D., van der Horst,
C.M., Harrison, T.S., 2010. Combination ﬂucytosine and high-dose ﬂuconazole
compared with ﬂuconazole monotherapy for the treatment of cryptococcal
meningitis: a randomized trial in Malawi. Clin. Infect. Dis. 50, 338–344.
Park, B.J., Wannemuehler, K.A., Marston, B.J., Govender, N., Pappas, P.G., Chiller, T.M.,
2009. Estimation of the current global burden of cryptococcal meningitis among
persons living with HIV/AIDS. AIDS 23, 525–530.
Perfect, J.R., 2013. Fungal diagnosis: how do we do it and can we do better? Curr.
Med. Res. Opin. 29 (Suppl. 4), 3–11.
Perfect, J.R., Dismukes, W.E., Pappas, P.G., Singh, N., Harrison, T.E., Lortholary, O.,
Dromer, F., Sobel, J.D., Sorrell, T.C., Goldman, D.L., Nuygen, M.H., Hammil, R.D.,
Larsen, R.A., Powderly, W.G., Graybill, J.R., 2010. Clinical practice guidelines for
the management of cryptococcal disease: 2010 Update by the Infectious
Diseases Society of America. Clin. Infect. Dis. 50, 291–322.
Posteraro, B., Vella, A., Cogliati, M., De Carolis, E., Florio, A.R., Posteraro, P.,
Sanguinetti, M., Tortorano, A.M., 2012. Matrix-assisted laser desorption
ionization-time of ﬂight mass spectrometry-based method for discrimination
between molecular types of Cryptococcus neoformans and Cryptococcus gattii. J.
Clin. Microbiol. 50, 2472–2476.
Pyrgos, V., Seitz, A.E., Steiner, C.A., Prevots, D.R., Williamson, P.R., 2013.
Epidemiology of cryptococcal meningitis in the US: 1997–2009. PLoS One 8,
e56269.
Robertson, E.J., Najjuka, G., Rolfes, M.A., Akampurira, A., Jain, N., Anantharanjit, J.,
von Hohenberg, M., Tassieri, M., Carlsson, A., Meya, D.B., Harrison, T.S., Fries,
B.C., Boulware, D.R., Bicanic, T., 2014. Cryptococcus neoformans ex vivo capsule
size is associated with intracranial pressure and host immune response in HIV-
associated cryptococcal meningitis. J. Infect. Dis. 209, 74–82.Rohatgi, S., Gohil, S., Kuniholm, M.H., Schultz, H., Dufaud, C., Armour, K.L., Badri, S.,
Mailliard, R.B., Pirofski, L.-a., 2013. Fc gamma receptor 3A polymorphism and
risk for HIV-associated cryptococcal disease. mBio 4, e00573-13.
Rolfes, M.A., Hullsiek, K.H., Rhein, J., Nabeta, H.W., Taseera, K., Schutz, C., Musubire,
A., Rajasingham, R., Williams, D.A., Thienemann, F., Muzoora, C., Meintjes, G.,
Meya, D.B., Boulware, D.R., 2014. The effect of therapeutic lumbar punctures on
acute mortality from cryptococcal meningitis. Clin. Infect. Dis. 59 (in press).
Rosen, L.B., Freeman, A.F., Yang, L.M., Jutivorakool, K., Olivier, K.N., Angkasekwinai,
N., Suputtamongkol, Y., Bennett, J.E., Pyrgos, V., Williamson, P.R., Ding, L.,
Holland, S.M., Browne, S.K., 2013. Anti-GM-CSF autoantibodies in patients with
cryptococcal meningitis. J. Immunol. 190, 3959–3966.
Rugemalila, J., Maro, V.P., Kapanda, G., Ndaro, A.J., Jarvis, J.N., 2013. Cryptococcal
antigen prevalence in HIV-infected Tanzanians: a cross-sectional study and
evaluation of a point-of-care lateral ﬂow assay. Trop. Med. Int. Health 18, 1075–
1079.
Saijo, T., Chen, J., Chen, S.C., Rosen, L.B., Yi, J., Sorrell, T.C., Bennett, J.E., Holland, S.M.,
Browne, S.K., Kwon-Chung, K.J., 2014. Anti-granulocyte-macrophage colony-
stimulating factor autoantibodies are a risk factor for central nervous system
infection by Cryptococcus gattii in otherwise immunocompetent patients. mBio
5, e00912-14.
Seaton, R.A., Verma, N., Naraqi, S., Wembri, J.P., Warrell, D.A., 1997. The effect of
corticosteroids on visual loss in Cryptococcus neoformans var. gattii meningitis.
Trans. R. Soc. Trop. Med. Hyg. 91, 50–52.
Siddiqi, O.K., Ghebremichael, M., Dang, X., Atadzhanov, M., Kaonga, P., Khoury, M.N.,
Koralnik, I.J., 2014. Molecular diagnosis of central nervous system opportunistic
infections in HIV-infected Zambian adults. Clin. Infect. Dis. 58, 1771–1777.
Siddiqui, A.A., Brouwer, A.E., Wuthiekanun, V., Jaffar, S., Shattock, R., Irving, D.,
Sheldon, J., Chierakul, W., Peacock, S., Day, N., White, N.J., Harrison, T.S., 2005.
IFN-gamma at the site of infection determines rate of clearance of infection in
cryptococcal meningitis. J. Immunol. 174, 1746–1750.
Sionov, E., Lee, H., Chang, Y.C., Kwon-Chung, K.J., 2010. Cryptococcus neoformans
overcomes stress of azole drugs by formation of disomy in speciﬁc multiple
chromosomes. PLoS Pathog. 6, e1000848.
Sionov, E., Chang, Y.C., Kwon-Chung, K.J., 2013. Azole heteroresistance in
Cryptococcus neoformans: emergence of resistant clones with chromosomal
disomy in the mouse brain during ﬂuconazole treatment. Antimicrob. Agent
Chemother. 57, 5127–5130.
Smith, R.M., Mba-Jonas, A., Tourdjman, M., Schimek, T., DeBess, E., Marsden-Haug,
N., Harris, J.R., 2014. Treatment and outcomes among patients with
Cryptococcus gattii infections in the United States Paciﬁc Northwest. PLoS One
9, e88875.
van der Horst, C.M., Saag, M.S., Cloud, G.A., Hamill, R.J., Graybill, J.R., Sobel, J.D.,
Johnson, P.C., Tuazon, C.U., Kerkering, T., Moskovitz, B.L., Powderly, W.G.,
Dismukes, W.E., 1997. Treatment of cryptococcal meningitis associated with the
acquired immunodeﬁciency syndrome. National Institute of Allergy and
Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N.
Engl. J. Med. 337, 15–21.
Van Wyk, M., Govender, N.P., Mitchell, T.G., Litvintseva, A.P.GERMS-SA., 2014.
Multilocus sequence typing of serially collected isolates of Cryptococcus from
HIV-infected patients in South Africa. J. Clin. Microbiol. 52, 1921–1931.
Wiesner, D.L., Moskalenko, O., Corcoran, J.M., McDonald, T., Rolfes, M.A., Meya, D.B.,
Kajumbula, H.A.K., Bohjanen, P.R., Knight, J.F., Boulware, D.R.K.N., 2012.
Cryptococcal genotype inﬂuences immunologic response and human clinical
outcome after meningitis. mBio 3, e00196-12.
Zhu, L.P., Wu, J.Q., Xu, B., Ou, X.T., Zhang, Q.Q., Weng, X.H., 2010. Cryptococcal
meningitis in non-HIV-infected patients in a Chinese tertiary care hospital,
1997–2007. Med. Mycol. 48, 570–579.
